Oncocross Co., Ltd.
KOSDAQTotal Valuation
Oncocross Co., Ltd. carries a market capitalization of 44.64B, placing it among publicly traded companies globally. Its enterprise value stands at 69.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 44.64B |
| Enterprise Value | 69.50B |
Valuation Ratios
The price-to-sales ratio is 185.93, and the price-to-book ratio stands at -1.62.
| PE Ratio | N/A |
| PS Ratio | 185.93 |
| PB Ratio | -1.62 |
| P/TBV Ratio | 7.58 |
| P/FCF Ratio | -22.79 |
| P/OCF Ratio | -14.09 |
Enterprise Valuation
| EV / Sales | 146.26 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Oncocross Co., Ltd. maintains a current ratio of 3.75, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.77, indicating elevated leverage, while an interest coverage ratio of -10.20 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.75 |
| Quick Ratio | 3.64 |
| Debt / Equity | 71.77 |
| Debt / EBITDA | -0.94 |
| Interest Coverage | -10.20 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -34.39 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Oncocross Co., Ltd.'s stock has declined approximately -66.81777% over the past 52 weeks. The 50-day moving average sits at 6,070.80, while the 200-day moving average is 8,353.40.
| Beta (5Y) | N/A |
| 52-Week Price Change | -66.81777% |
| 50-Day Moving Average | 6,070.80 |
| 200-Day Moving Average | 8,353.40 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Oncocross Co., Ltd. generated 475.15M in revenue and converted that into -9.31B in net income, yielding earnings per share of -774.44. EBITDA reached -8.96B, while operating income came in at -8.96B.
| Revenue | 475.15M |
| Gross Profit | 492.48M |
| Operating Income | -8.96B |
| Pretax Income | -9.31B |
| Net Income | -9.31B |
| EBITDA | -8.96B |
| EBIT | -8.96B |
| Earnings Per Share (EPS) | -774.44 |
Balance Sheet
Oncocross Co., Ltd. holds 27.25B in cash and equivalents against 8.40B in total debt, resulting in a net debt position of 6.71B. Total book value stands at -54.66B, with working capital of 20.64B providing operational flexibility.
| Cash & Cash Equivalents | 27.25B |
| Total Debt | 8.40B |
| Net Debt | 6.71B |
| Equity (Book Value) | -54.66B |
| Book Value Per Share | -4,547.51 |
| Working Capital | 20.64B |
Cash Flow
Oncocross Co., Ltd. produced -6.27B in operating cash flow over the past twelve months. After subtracting -2.39B in capital expenditures, free cash flow totaled -8.66B - equivalent to -720.70 per share.
| Operating Cash Flow | -6.27B |
| Capital Expenditures | -2.39B |
| Free Cash Flow | -8.66B |
| FCF Per Share | -720.70 |
Margins
Oncocross Co., Ltd. operates with a gross margin of 92.33, reflecting its pricing power and cost economics. The operating margin of -1,885.48 and net profit margin of -1,959.09 provide insight into operational efficiency.
| Gross Margin | 92.33 |
| Operating Margin | -1,885.48 |
| Pretax Margin | -1,959.09 |
| Profit Margin | -1,959.09 |
| EBITDA Margin | -1,885.48 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -23.37 |
| FCF Yield | -4.39 |
Scores
Oncocross Co., Ltd. posts an Altman Z-Score of -0.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.27 |